Study Details

Back to Search Results

A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02528643

Astellas Study ID

The unique identification code given by the study sponsor.

9785-CL-3021

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2014-004283-37

Follow Trial

Condition

Liver Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

enzalutamide

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Nov 2015 - Feb 2021

Masking

Double (Participant, Investigator)

Enrollment number

165

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site KR82004

Seoul, Republic of Korea, 05505

Site US10017

Minneapolis, United States, 55455-0362

Site KR82002

Seongnam-Si, Republic of Korea, 013620

Site ES34002

Santiago de Compostela, Spain, 15706

Site TW88605

Tainan, Taiwan, Province of China, 710

Site IT39004

Pavia, Italy, 27100

Site US10008

Portland, United States, 97239

Site GB44007

Birmingham, United Kingdom, B15 2WB

Site ES34006

Cordoba, Spain, 14004

Site US10003

San Francisco, United States, 94115

Site US10002

Spartanburg, United States, 29303

Site ES34003

Barcelona, Spain, 08035

Site IT39001

Napoli, Italy, 80131

Site CA15001

Toronto, Canada, M5G2C4

Site CA15002

Montreal, Canada, H3T 1E2

Site KR82006

Seoul, Republic of Korea, 03080

Site US10009

Skokie, United States, 60077

Site IT39005

Benevento, Italy

Site US10015

Nashville, United States, 37208

Site IT39002

Milan, Italy, 20132

Site US10011

St. Louis, United States, 63104

Site ES34004

Madrid, Spain, 28222

Site US10001

San Juan, United States, 00927

Site US10021

Lebanon, United States, 03756-1000

Site GB44008

London, United Kingdom, W12 OHS

Site US10022

San Antonio, United States, 78215-1639

Site US10010

Columbus, United States, 43210

Site GB44005

Manchester, United Kingdom, M20 4BX

Site US10019

Philadelphia, United States, 19104

Site US10020

Evanston, United States, 60201

Site IT39008

Rozzano, Italy, 20089

Site HK85204

Shatin, Hong Kong, 999077

Site CA15003

Montreal, Canada, H4A 3J1

Site IT39006

Milano, Italy, 20122

Site US10014

Philadelphia, United States, 19104

Site HK85205

Tuen Mun, Hong Kong, 999077

Site US10016

Milwaukee, United States, 53226-3522

Site TW88603

Douliu, Taiwan, Province of China, 640

Site HK85202

Kowloon, Hong Kong, 999077

Site TW88604

Taipei City, Taiwan, Province of China, 10048

Site GB44004

London, United Kingdom, SE5 9RS

Site GB44002

Wirral, United Kingdom, CH63 4JY

Site KR82001

Seoul, Republic of Korea, 06591

Site KR82007

Seoul, Republic of Korea, 03722

Site IT39011

Padova, Italy, 35128

Site TW88606

Tainan, Taiwan, Province of China, 704

Site KR82005

Seoul, Republic of Korea, 135-710

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo